Heparin Market Size - By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Source (Porcine, Bovine), By Application (Venous Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel, Global Forecast (2023 - 2032)

Heparin Market Size - By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Source (Porcine, Bovine), By Application (Venous Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel, Global Forecast (2023 - 2032)

Heparin Market Size

Heparin Market size was worth over USD 4.8 billion in 2022. Driven by the high prevalence rate of chronic disorders globally, the industry could grow at over 2.5% CAGR from 2023 to 2032.
 

Surging occurrence of chronic disorders such as coronary artery disease, thromboembolism, and others that result in blood clot formation has increased the need for heparin. As per CDC, in 2021, 2 in every 10 mortalities from coronary artery disease occurred in adults below the age of 65 years. Moreover, the growing demand for anticoagulants in hemodialysis, open heart surgery, and other interventional procedures will create ample opportunities for industry expansion.
 

Impact of COVID-19 Pandemic

The COVID-19 pandemic asserted a positive impact on the heparin market. Since heparin helps subdue respiratory diseases and thin the blood, a spike in COVID-19 cases increased the product uptake. Additionally, the growing occurrence of venous thromboembolism in COVID-19 patients further bolstered the need for anticoagulants such as heparin. Moreover, rising investments by the government towards strengthening their healthcare infrastructure, coupled with growing efforts by product manufacturers towards innovations will further positively affect the industry landscape in the post-COVID-19 era. 
 

Heparin Market Trends

Recent advancements in hemodialysis have created lucrative opportunities for market progression. These advancements have increased the demand for high-flux dialyzers, which enhance clearance rates for toxins and fluid removal and require longer treatment times. To prevent clotting in the dialysis circuit during these prolonged treatments, heparin is commonly used as an anticoagulant. Researchers are actively exploring and developing heparin-sparing techniques in hemodialysis, which will positively impact industry expansion.
 

Heparin Market Analysis

Based on the product, the low molecular weight heparin market was valued at over USD 4.2 billion in 2022. Growing occurrence of deep vein thrombosis has increased the need for low molecular weight heparin. As per CDC, around 60,000-100,000 Americans die of this condition every year. Moreover, low molecular weight heparin has a longer shelf-life, reduces and eliminates hospital stays, and can be self-administered at home via subcutaneous injection, which favors its mass adoption. 
 

With respect to application, the market size from the venous thromboembolism segment could expand at over 2% CAGR from 2023 to 2032. Growing prevalence of venous thromboembolism has increased the need for heparin. Moreover, recent innovations in the development of novel heparin products to overcome the limitation of current treatment options for venous thromboembolism are further contributing to segment growth. Many industry players are focusing on developing enhanced capabilities of heparin to extend their footprint, creating a robust growth outlook for the heparin industry. 
 

From the regional perspective, Europe heparin market share reached more than 58.5% in 2022. Growing prevalence of venous thromboembolism, ischemic heart disease, and other cardiovascular diseases that lead to blood clot formation has increased the need for heparin in Europe. As per the European Society of Cardiology, cardiovascular disorders lead to around 3.9 million mortalities annually in the region. Moreover, regional expansion can also be attributed to rising awareness about novel oral anticoagulants. 
 

Heparin Market Share

• Shenzhen Hepalink
• Nanjing King-Friend Biochemical Pharmaceutical
• Fresenius Kabi
• Changzhou Qianhong Biopharma
•  Yantai Dongcheng Biochemicals Co., Ltd.
   

Heparin Industry News

•  In May 2022, Fresenius Kabi, a leading pharmaceutical company, acquired Ivenix, Inc., a prominent infusion therapy company. 
   
• In February 2022, Techdow USA Inc., an injectables company, unveiled the launch of Heparin Sodium Injection, USP in the U.S. This strategy helped the company strengthen its market position.
   

The heparin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2028 to 2032, for the following segments

Click here to Buy Section of this Report

Market Size, By Product

• Low molecular weight heparin
• Unfractionated heparin

Market Size, By Source

• Porcine
• Bovine

Market Size, By Application

• Venous thromboembolism
• Atrial fibrillation/flutter
• Coronary artery disease
• Other applications

Market Size, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Austria
  • Poland
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa